Back to search results

A Study of MK-8527 in Healthy Adults

This study is looking at a medicine called MK-8527 in healthy adults aged 18 to 55. Researchers want to understand how MK-8527 works in the body when taken with food, or with other medicines like Probenecid or Itraconazole. They will measure how much MK-8527 is in your blood over time. The study also aims to check the safety of MK-8527 and how well people tolerate it. To join, you need to be in good health with a body mass index (BMI) between 18 and 32. The study plans to enroll 44 participants, but its current status is unclear.

Study design
This interventional study plans to enroll 44 healthy participants. It will investigate how MK-8527 interacts with food and other medications.
What's involved
You would take MK-8527, Probenecid, or Itraconazole as oral tablets or solution. Blood samples will be taken at specific times up to 336 hours (14 days) after your dose.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels of MK-8527 will be measured for up to 336 hours (14 days) after your dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07661108

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

Recruiting
PHASE1Ages 18–55InterventionalBasic science
Merck Sharp & Dohme LLC
~44 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:MK-8527ProbenecidItraconazole

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without Food
Measured over Predose and at designated timepoints (up to 336 hours postdose)
+2 more outcomes measured

Conditions

Healthy

Explore related trials

Healthy Volunteers

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

Toll Free Number
[email protected]
1-888-577-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be in good health
Has a body mass index (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion

Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m\^2
Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
Has a history of cancer (malignancy)
Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)

What this trial measures

  • Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without FoodPredose and at designated timepoints (up to 336 hours postdose)

    Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.

  • Part 2: AUC0-inf of MK-8527 in Plasma With and Without ProbenecidPredose and at designated timepoints (up to 336 hours postdose)

    Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.

  • Part 3: AUC0-inf of MK-8527 in Plasma With and Without ItraconazolePredose and at designated timepoints (up to 336 hours postdose)

    Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.